PartnershipJul 9, 2026, 04:07 PM
Rani Therapeutics Partners with PegBio for Oral Obesity Drug Delivery
AI Summary
Rani Therapeutics Holdings, Inc. has announced a research and development collaboration with PegBio Co., Ltd. The partnership aims to explore the oral delivery of multiple novel candidates from PegBio's obesity and metabolic disease pipeline using Rani's proprietary RaniPill® platform. This collaboration is expected to expand Rani's obesity franchise and advance promising molecules into clinical development, reflecting confidence in the versatility of the RaniPill® technology.
Key Highlights
- Rani Therapeutics announced a research and development collaboration with PegBio Co., Ltd.
- The partnership will explore oral delivery of PegBio's obesity and metabolic disease molecules.
- The collaboration leverages Rani's proprietary RaniPill® platform.
- Goal is to advance promising candidates into clinical development.
- The agreement expands Rani's obesity franchise beyond existing programs.
- Rani's existing obesity pipeline includes RT-114 (GLP-1/GLP-2 dual agonist) in Phase 1.
- Rani has also completed preclinical studies for other obesity candidates like semaglutide.
Price Impact
More from RANI